New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 6, 2013
11:49 EDTAMAGAMAG sees FY13 COGS of between 14% and 18% of net product sales
AMAG sees FY13 cost of goods sold, COGS, of between 14% and 18% of net product sales; Total operating expenses, excluding COGS, of between $78M and $82M, representing an approximate 10% reduction from 2012. The reduced operating expenses in 2013 will be driven by decreased clinical trial costs, offset in part by new investments in a lower-cost production process and pre-launch investments to support a potential expansion to Feraheme’s label. The company expects: Research and development expenses of between $24M and $27M, representing an approximate 27% reduction from 2012; Selling, general and administrative expenses of between $54M and $57M, representing an approximate 2% increase from 2012.
News For AMAG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 28, 2016
10:05 EDTAMAGOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AMAG Pharmaceuticals (AMAG) initiated with an Outperform at Northland... Angie's List (ANGI) initiated with a Neutral at Roth Capital... Bio Blast Pharma (ORPN) initiated with a Buy at Rodman & Renshaw... British American Tobacco (BTI) initiated with a Buy at UBS... Imperial Tobacco (ITYBY) initiated with a Buy at UBS... Instructure (INST) initiated with an Outperform at Barrington... Nektar (NKTR) initiated with a Buy at Janney Capital... Par Pacific (PARR) initiated with an Outperform at Imperial Capital... Pure Storage (PSTG) initiated with a Buy at Maxim... comScore (SCOR) initiated with a Hold at Evercore ISI.
06:51 EDTAMAGAMAG Pharmaceuticals initiated with an Outperform at Northland
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use